The glutamate hypothesis of schizophrenia models the subset of pathologic mechanisms linked to glutamatergic
 signaling. The hypothesis was initially based on a set of clinical, 
neuropathological, and, later, genetic findings pointing at a 
hypofunction of glutamatergic signaling via NMDA receptors. While thought to be more proximal to the root causes of schizophrenia, it does not negate the dopamine hypothesis, and the two may be ultimately brought together by circuit-based models.
 The development of the hypothesis allowed for the integration of the 
GABAergic and oscillatory abnormalities into the converging disease 
model and made it possible to discover the causes of some disruptions.
Like the dopamine hypothesis, the development of the glutamate hypothesis developed from the observed effects of mind-altering drugs. However, where dopamine agonists can mimic positive symptoms with significant risks to brain structures during and after use, NMDA antagonists mimic some positive and negative symptoms with less brain harm, when combined with a GABAA activating drug. Likely, both dopaminergic and glutaminergic abnormalities are implicated in schizophrenia, from a profound alteration in the function of the chemical synapses, as well as electrical synaptic irregularities. These form a portion of the complex constellation of factors, neurochemically, psychologically, psychosocially, and structurally, which result in schizophrenia.
Like the dopamine hypothesis, the development of the glutamate hypothesis developed from the observed effects of mind-altering drugs. However, where dopamine agonists can mimic positive symptoms with significant risks to brain structures during and after use, NMDA antagonists mimic some positive and negative symptoms with less brain harm, when combined with a GABAA activating drug. Likely, both dopaminergic and glutaminergic abnormalities are implicated in schizophrenia, from a profound alteration in the function of the chemical synapses, as well as electrical synaptic irregularities. These form a portion of the complex constellation of factors, neurochemically, psychologically, psychosocially, and structurally, which result in schizophrenia.
The role of heteromer formation
Alteration
 in the expression, distribution, autoregulation, and prevalence of 
specific glutamate heterodimers alters relative levels of paired G 
proteins to the heterodimer-forming glutamate receptor in question. 
Namely: 5HT2A and mGlu2 form a dimer which mediates psychotomimetic and entheogenic effects of psychedelics; as such this receptor is of interest in schizophrenia. Agonists at either constituent receptor may modulate the other receptor allosterically;
 e.g. glutamate-dependent signaling via mGlu2 may modulate 5HT2A-ergic 
activity. Equilibrium between mGlu2/5HT2A is altered against tendency 
towards of psychosis by neuroleptic-pattern 5HT2A antagonists and mGlu2 
agonists; both display antipsychotic activity. AMPA, the most widely 
distributed receptor in the brain, is a tetrameric ionotropic receptor; 
alterations in equilibrium between constituent subunits are seen in 
mGlu2/5HT2A antagonist (antipsychotic) administration GluR2 is seen to be upregulated in the PFC while GluR1 downregulates in response to antipsychotic administration. 
Reelin abnormalities may also be involved in the pathogenesis of 
schizophrenia via a glutamate-dependent mechanism. Reelin expression 
deficits are seen in schizophrenia, and reelin enhances expression of 
AMPA and NMDA alike.
 As such deficits in these two ionotropic glutamate receptors may be 
partially explained by altered reelin cascades. Neuregulin 1 deficits 
may also be involved in glutaminergic hypofunction as NRG1 hypofunction 
leads to schizophrenia-pattern behavior in mice; likely due in part to 
reduced NMDA signaling via Src suppression.
The role of synaptic pruning
Various
 neurotrophic factors dysregulate in schizophrenia and other mental 
illnesses, namely BDNF; expression of which is lowered in schizophrenia 
as well as in major depression and bipolar disorder. BDNF regulates in an AMPA-dependent mechanism - AMPA and BDNF alike are critical mediators of growth cone survival. NGF, another neurotrophin involved in maintenance of synaptic plasticity is similarly seen in deficit.
Dopaminergic excess, classically understood to result in 
schizophrenia, puts oxidative load on neurons; leading to inflammatory 
response and microglia activation. Similarly, toxoplasmosis infection in
 the CNS (positively correlated to schizophrenia) activates inflammatory
 cascades, also leading to microglion activation. The lipoxygenase-5 
inhibitor minocycline has been seen to be marginally effective in 
halting schizophrenia progression. One of such inflammatory cascades' 
downstream transcriptional target, NF-κB, is observed to have altered expression in schizophrenia.
In addition, CB2 is one of the most widely distributed glial cell-expressed receptors, downregulation
 of this inhibitory receptor may increase global synaptic pruning 
activity. While difference in expression or distribution is observed, when the CB2 receptor is knocked out in mice, schizophreniform behaviors manifest.
 This may deregulate synaptic pruning processes in a tachyphlaxis 
mechanism wherein immediate excess CB2 activity leads to phosphorylation
 of the receptor via GIRK, resultant in b-arrestin-dependent internalization and subsequent trafficking to the proteasome for degradation.
The role of endogenous antagonists
Alterations in production of endogenous NMDA antagonists such as agmatine and kyenurenic acid have been shown in schizophrenia.
 Deficit in NMDA activity produces psychotomimetic effects, though it 
remains to be seen if the blockade of NMDA via these agents is causative
 or actually mimetic of patterns resultant from monoaminergic 
disruption.
AMPA, the most widely distributed receptor in the brain, mediates
 long term potentiation via activity-dependent modulation of AMPA 
density. GluR1 subunit-containing AMPA receptors are Ca2+ permeable 
while GluR2/3 subunit-positive receptors are nearly impermeable to 
calcium ions. In the regulated pathway, GluR1 dimers populate the 
synapse at a rate proportional to NMDA-ergic Ca2+ influx. In the 
constitutative pathway, GluR2/3 dimers populate the synapse at a steady 
state.
This forms a positive feedback loop, where a small trigger 
impulse degating NMDA from Mg2+ pore blockade results in calcium influx,
 this calcium influx then triggers trafficking of GluR1-containing(Ca2+ 
permeable) subunits to the PSD, such trafficking of GluR1-positive AMPA 
to the postsynaptic neuron allows for upmodulation of the postsynaptic 
neuron's calcium influx in response to presynaptic calcium influx. 
Robust negative feedback at NMDA from kyenurenic acid, magnesium, zinc, 
and agmatine prevents runaway feedback.
Misregulation of this pathway would sympathetically dysregulate 
LTP via disruption of NMDA. Such alteration in LTP may play a role, 
specifically in negative symptoms of schizophrenia, in creation of more 
broad disruptions such as loss of brain volume; an effect of the disease
 which antidopaminergics actually worsen, rather than treat.
The role of a7 nicotinic
Anandamide,
 an endocannabinoid, is an a7 nicotinic antagonist. Cigarettes, consumed
 far out of proportion by schizophrenics, contain nornitrosonicotine; a 
potent a7 antagonist. This may indicate a7 pentameter excess as a 
causative factor, or possibly as a method of self-medication to combat 
antipsychotic side effects. Cannabidiol, a FAAH inhibitor, increases 
levels in anandamide and may have antipsychotic effect; though results 
are mixed here as anandamide also is a cannabinoid and as such displays 
some psychotomimetic effect. However, a7 nicotinic agonists have 
been indicated as potential treatments for schizophrenia, though 
evidence is somewhat contradictory there is indication a7 nAChR is 
somehow involved in the pathogenesis of schizophrenia.
The role of 5-HT
This deficit in activation also results in a decrease in activity of 5-HT1A receptors in the raphe nucleus. This serves to increase global serotonin levels, as 5-HT1A serves as an autoreceptor.  The 5-HT1B receptor, also acting as an autoreceptor, specifically within the striatum, but also parts of basal ganglia
 then will inhibit serotonin release. This disinhibits frontal dopamine 
release. The local deficit of 5-HT within the striatum, basal ganglia, 
and prefrontal cortex causes a deficit of excitatory 5-HT6
 signalling. This could possibly be the reason antipsychotics sometimes 
are reported to aggravate negative symptoms as antipsychotics are 5HT6 antagonists
 This receptor is primarily GABAergic, as such, it causes an excess of 
glutamatergic, noradrenergic, dopaminergic, and cholinergic activity 
within the prefrontal cortex and the striatum. An excess of 5-HT7 signaling within the thalamus
 also creates too much excitatory transmission to the prefrontal cortex.
 Combined with another critical abnormality observed in schizoid 
patients: 5-HT2A dysfunction, this altered signalling cascade creates cortical, thus cognitive abnormalities. 5-HT2A
 allows a link between cortical, thus conscious, and the basal ganglia, 
unconscious. Axons from 5-HT2A neurons in layer V of the cerebral cortex reach the basal ganglia, forming a feedback loop. Signalling from layer V of the cerebral cortex to the basal ganglia alters 5-HT2C signalling. This feedback loop with 5-HT2A/5-HT2C is how the outer cortex layers can exert some control over our neuropeptides, specifically opioid peptides, oxytocin and vasopressin.
 This alteration in this limbic-layer V axis may create the profound 
change in social cognition (and sometimes cognition as a whole) that is 
observed in schizoid patients. However, genesis of the actual 
alterations is a much more complex phenomena.
The role of inhibitory transmission
The cortico-basal ganglia-thalamo-cortical loop
 is the source of the ordered input necessary for a higher level upper 
cortical loop. Feedback is controlled by the inhibitory potential of the
 cortices via the striatum. Through 5-HT2A efferents from layer V of the
 cortex transmission proceeds through the striatum into the globulus 
pallidus internal and substantia nigra pars compacta. This core input to
 the basal ganglia is combined with input from the subthalamic nucleus. 
The only primarily dopaminergic pathway in this loop is a reciprocal 
connection from the substantia nigra pars reticulata to the striatum. 
Dopaminergic drugs such as dopamine releasing agents and direct 
dopamine receptor agonists create alterations in this primarily 
GABAergic pathway via increased dopaminergic feedback from the 
substantia nigra pars compacta to the striatum. However, dopamine also 
modulates other cortical areas, namely the VTA; with efferents to the 
amygdala and locus coeruleus, likely modulating anxiety and paranoid 
aspects of psychotic experience. As such, the glutamate hypothesis is 
probably not an explanation of primary causative factors in positive 
psychosis, but rather might possibly be an explanation for negative 
symptoms. 
Dopamine hypothesis of schizophrenia elaborates upon the nature of abnormal lateral structures found in someone with a high risk for psychosis.
Altered signalling cascades
Again,
 thalamic input from layer V is a crucial factor in the functionality of
 the human brain. It allows the two sides to receive similar inputs, 
thus be able to perceive the same world. In psychosis, thalamic input 
loses much of its integrated character: hyperactive core feedback loops 
overwhelm the ordered output.
 This is due to excessive D2 and 5-HT2A activity. This alteration in 
input to the top and bottom of the cortex. The altered 5-HT signal 
cascade enhances the strength of excitatory thalamic input from layer V.
 This abnormality, enhancing the thalamic-cortical transmission cascade 
versus the corticostriatal control, creates a feedback loop, resulting 
in abnormally strong basal ganglia output.
The root of psychosis (experiences that cannot be explained, even
 within their own mind) is when basal ganglia input to layer V 
overwhelms the inhibitory potential of the higher cortexies resulting 
from striatal transmission. When combined with the excess prefrontal, 
specifically orbitofrontal transmission, from the hippocampus, this creates a brain prone to falling into self reinforcing belief.
However, given a specific environment, a person with this kind of
 brain (a human) can create a self-reinforcing pattern of maladaptive 
behavior, from the altered the layer II/III and III/I axises, from the 
disinhibited thalamic output. Rationality is impaired, primarily as 
response to the deficit of oxytocin and excess of vasopressin from the 
abnormal 5HT2C activity.
Frontal cortex activity will be impaired, when combined with 
excess DA activity: the basis for the advancement of schizophrenia, but 
it is also the neurologic mechanism behind many other psychotic diseases
 as well.. Heredation of schizophrenia may even be a result of 
conspecific "refrigerator parenting" techniques passed on though 
generations. However, the genetic component is the primary source of the
 neurological abnormalities which leave one prone to psychological 
disorders. Specifically, there is much overlap between bipolar disorder 
and schizophrenia, and other psychotic disorders.
Psychotic disorder is linked to excessive drug use, specifically dissociatives, psychedelics, stimulants, and marijuana.
Current state of schizophrenia treatment
Alterations in serine racemase indicate that the endogenous NDMA agonist D-serine may be produced abnormally in schizophrenia and that d-serine may be an effective treatment for schizophrenia. 
Schizophrenia is now treated by medications known as antipsychotics (or neuroleptics) that typically reduce dopaminergic activity because too much activity has been most strongly linked to positive symptoms,
 specifically persecutory delusions. Dopaminergic drugs do not induce 
the characteristic auditory hallucinations of schizophrenia.
 Dopaminergic drug abuse such as abuse of methamphetamine may result in a
 short lasting psychosis or provokation of a longer psychotic episode 
that may include symptoms of auditory hallucinations. The typical antipsychotics
 are known to have significant risks of side effects that can increase 
over time, and only show clinical effectiveness in reducing positive 
symptoms. Additionally, although newer atypical antipsychotics
 can have less affinity for dopamine receptors and still reduce positive
 symptoms, do not significantly reduce negative symptoms. A 2006 systematic review investigated the efficacy of glutamatergic drugs as add-on: 
| Summary | 
|---|
| In general, all glutamatergic drugs appeared to be ineffective in further reducing 'positive symptoms' of the illness when added to the existing antipsychotic treatment. Glycine and D-serine may somewhat improve 'negative symptoms' when added to regular antipsychotic medication, but the results were not fully consistent and data are too few to allow any firm conclusions. | 
| Outcome | Findings in words | Findings in numbers | Quality of evidence | 
|---|---|---|---|
| Global outcome | |||
| Relapse (add-on glycine)  | 
At present it is not possible to be confident about the effect of adding the glutamatergic drug to standard antipsychotic treatment. Data supporting this finding are very limited. | RR 0.39 (0.02 to 8.73) | Very low | 
| Service outcome | |||
| Hospital admission (add-on glycine)  | 
There is no clarity about the benefits or otherwise of adding a glutamatergic drug to antipsychotics for outcomes about how much hospital/community care is used. Data supporting this finding are based on low quality evidence. | RR 2.63 (0.12 to 59.40) | Low | 
| Mental state | |||
| No clinically significant improvement (add-on glycine)  | 
There is no evidence of clear advantage of using add-on glutamatergic to standard antipsychotic medication. These findings are based on data of low quality. | RR 0.92 (0.79 to 1.08) | Low | 
| Adverse effects | |||
| Constipation (add-on glycine or D-serine)  | 
There is no clarity from very limited data. Additional glutamatergic could cause constipation or help avoid it. Data are very limited. | RR 0.61 (0.06 to 6.02) | Very low | 
| Insomnia (add-on glycine or D-serine)  | 
Additional glutamatergic may help or cause insomnia - it is not clear from the very limited data. | RR 0.61 (0.13 to 2.84) | Very low | 
| Missing outcomes | |||
| Quality of life | This outcome was not reported in any studies | 
 | |
Psychotomimetic glutamate antagonists
Ketamine and PCP
 were observed to produce significant similarities to schizophrenia. 
Ketamine produces more similar symptoms (hallucinations, withdrawal) 
without observed permanent effects (other than ketamine tolerance). Both
 arylcyclohexamines have some(uM) affinity to D2 and as triple reuptake 
inhibitors. PCP is representative symptomatically, but does appear to 
cause brain structure changes seen in schizophrenia. Although unconfirmed, Dizocilpine
 discovered by a team at Merck seems to model both the positive and 
negative effects in a manner very similar to schizophreniform disorders.
Possible glutamate based treatment
An early clinical trial by Eli Lilly of the drug LY2140023 has shown potential for treating schizophrenia without the weight gain and other side-effects associated with conventional anti-psychotics. A trial in 2009 failed to prove superiority over placebo or Olanzapine, but Lilly explained this as being due to an exceptionally high placebo response. However, Eli Lilly terminated further development of the compound in 2012 after it failed in phase III clinical trials. This drug acts as a selective agonist at metabotropic mGluR2 and mGluR3 glutamate receptors (the mGluR3 gene has previously been associated with schizophrenia.).
Studies of glycine (and related co-agonists at the NMDA receptor) added to conventional anti-psychotics have also found some evidence that these may improve symptoms in schizophrenia.
Animal models
Research done on mice in early 2009 has shown that when the neuregulin-1\ErbB post-synaptic receptor genes are deleted, the dendritic spines
 of glutamate neurons initially grow, but break down during later 
development. This led to symptoms (such as disturbed social function, 
inability to adapt to predictable future stressors) that overlap with 
schizophrenia.
 This parallels the time delay for symptoms setting in with 
schizophrenic humans who usually appear to show normal development until
 early adulthood.
Disrupted in schizophrenia 1 is a gene that is disrupted in schizophrenia.